GlassScriptPhysician profile
Douglas B Kliewer
NPI 1174518906
$9,843.81
in general payments reported to CMS, 2019-2025
38 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $602 · 2021: $1,220 · 2022: $1,437 · 2023: $1,786 · 2024: $2,117 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,601 · Education: $18.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,601.20 |
| Education | $18.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,577.27 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,279.79 | 2019-2025 | Entyvio, Eohilia, Vpriv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,099.42 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Janssen Biotech, INC. | $899.15 | 2019-2025 | Stelara, Tremfya, Remicade |
| Pfizer INC. | $559.15 | 2019-2025 | |
| Gilead Sciences, INC. | $435.79 | 2019-2025 | |
| Lilly USA, LLC | $338.84 | 2023-2025 | Omvoh |
| Celgene Corporation | $338.08 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $311.62 | 2019-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $245.70 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $212.37 | 2022-2025 | Dupixent |
| Daiichi Sankyo INC. | $201.35 | 2019-2024 | Enhertu, Injectafer |
| Olympus America INC. | $177.83 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $142.78 | 2020-2025 | Linzess |
| Genzyme Corporation | $129.18 | 2022-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $122.77 | 2024-2025 | Iqirvo |
| Braintree Laboratories, INC. | $114.13 | 2021 | |
| Merck Sharp & Dohme LLC | $98.95 | 2022-2024 | Dificid |
| Qol Medical, LLC | $78.44 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $72.23 | 2022-2024 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $50.70 | 2020-2023 | |
| Ardelyx, INC. | $47.58 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $40.64 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $34.80 | 2023 | Zeposia |
| Ucb, INC. | $30.47 | 2019 | |
| Allergan, INC. | $27.58 | 2019 | |
| Medtronic, INC. | $23.76 | 2025 | Interstim |
| Biocon Biologics INC | $19.34 | 2025 | Yesintek |
| Celltrion USA INC. | $18.49 | 2024 | Zymfentra |
| Mylan Institutional INC. | $16.92 | 2023 | Hulio |
| Redhill Biopharma INC. | $16.24 | 2021 | |
| Organon LLC | $15.14 | 2022 | |
| Alfasigma USA, INC. | $14.02 | 2020 | |
| Recordati_rare_diseases_inc. | $13.53 | 2023 | Panhematin |
| Phathom Pharmaceuticals, INC. | $13.47 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.36 | 2024 | Cyltezo |
| Endo Pharmaceuticals INC. | $12.93 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,097.44 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Kliewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.